Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Wary Of Future Competition In Renal Anemia Market

Executive Summary

The race to market for HIF-PH inhibitors to treat anemia associated with chronic kidney disease is highly competitive and will be complicated by the expected launch of biosimilar erythropoiesis-stimulating agents.

You may also be interested in...



Akebia Holds Development Reins In Anemia While Otsuka Jumps On Vadadustat Sleigh

Co-development deal worth $265m in near-term cash will allow Akebia to tap into Otsuka's established kidney disease infrastructure, while holding the reins on key aspects of commercialization.

GSK Kicks Off Two Large Outcomes Trials In A Competitive CKD Category

The company initiated a Phase III development program for the oral HIF-PH inhibitor daprodustat as a treatment for anemia associated with chronic kidney disease. Two trials will enroll 7,500 patients.

Japan Phase III Start Cements Roxadustat’s Lead

Astellas/FibroGen's oral candidate for anemia in chronic kidney disease has moved into Phase III in Japan on the basis of promising Phase II results, cementing the global development lead for the first-in-class product and taking it closer to a potentially big market.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC065112

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel